Vitamin D3 for Life

Live Enlightened

Article

Free, Albumin-Bound and Total Vitamin D in the Blood: Full Study

Previous related pageFree vs Total Vitamin D ExplainedNext related pageFree, Albumin-Bound and Total Vitamin D in the Blood: Study Summary
Study at a glance

How is vitamin D carried in the blood?

This page examines how 25-hydroxyvitamin D, the form measured in routine vitamin D tests, is carried in blood. Most is attached to vitamin D-binding protein, with some attached to another protein called albumin. A very small amount is unattached, or free. Total measurements count all these amounts together.

Who was studied to compare free and total vitamin D?

Researchers tested human blood samples and studied people with liver disease, whose carrier proteins can be reduced. Another study examined 472 adults taking part in a vitamin D supplement trial. Two rare cases involved people who could not make the usual vitamin D-binding protein. These studies addressed different questions about blood measurements.

When did free and total vitamin D measurements differ?

People with liver disease had lower total levels than comparison participants, but broadly similar amounts of free 25-hydroxyvitamin D. A higher percentage was free because the total amount was lower. Common inherited carrier differences affected total levels more clearly than directly measured free levels. The rare cases had extremely low total levels without equally severe disruption of calcium control, although one had important bone problems.

Do these studies show which vitamin D blood test is best?

Carrier proteins affect the relationship between total and free blood measurements. This does not mean low total levels are always harmless or that only free vitamin D matters. These studies do not establish which measurement best predicts every tissue’s response or leads to better health for patients. Rare cases cannot define normal blood-test targets for everyone.

Read the full article below ↓

Most circulating 25-hydroxyvitamin D is not floating freely in plasma. It is distributed between vitamin D-binding protein (DBP), albumin and a very small unbound fraction. This Full Study examines what those compartments mean physiologically, how the evidence established them, and why carrier dependence does not justify the simplistic claim that only free vitamin D matters. For a shorter route through the same evidence, see Free, Albumin-Bound and Total Vitamin D in the Blood: Study Summary.

The circulation contains three related vitamin D pools

The central physiological distinction is between concentration and binding state. Total 25(OH)D counts the circulating 25(OH)D present across all binding states. Free 25(OH)D is the tiny fraction not bound to a carrier at the moment of measurement. Between those two sits the albumin-bound fraction, which is more weakly bound than the much larger DBP-bound pool. These are not three different vitamin D molecules. They are different physical states of the same circulating metabolite, linked by reversible binding equilibria.

The classic direct binding work by Bikle and colleagues is important because it did more than infer this arrangement from modern terminology. The investigators measured the free fraction of 25(OH)D in human serum, characterised a high-affinity binding component consistent with DBP, and then experimentally depleted DBP to reveal lower-affinity residual binding attributable principally to albumin. In normal serum they estimated that roughly 88% of 25(OH)D was DBP-bound and about 0.03% was free, leaving most of the remainder associated with albumin. The exact percentages should not be treated as universal constants, but the compartment structure is physiologically informative.

The carrier biology behind that partitioning is developed separately in Vitamin D Binding Protein Explained and Vitamin D Transport Proteins. The point here is narrower: a total concentration is partly a measurement of the metabolite and partly a consequence of the proteins that carry it.

Why DBP dominates total circulating 25(OH)D

DBP has much higher affinity for 25(OH)D than albumin. That high affinity means the DBP-bound pool acts as the dominant circulating reservoir under ordinary conditions. Albumin is far more abundant as a plasma protein, but its affinity for 25(OH)D is much weaker. The result is a large tightly bound pool, a smaller more exchangeable albumin-associated pool and a minute instantaneous free fraction.

This equilibrium matters because a change in carrier abundance can change total concentration without requiring an equivalent change in the unbound fraction. Conversely, a change in total 25(OH)D cannot automatically be interpreted as an identical change in the amount immediately unbound. The relationship is usually close enough for total 25(OH)D to remain useful, but it is not physically identical.

The phrase “bioavailable vitamin D” is sometimes used for free plus albumin-bound 25(OH)D, borrowing a concept used for other protein-bound hormones. That label should be handled cautiously. Weaker albumin binding makes exchange with the free pool more plausible, but it does not prove that every tissue treats albumin-bound 25(OH)D as uniformly available or that DBP-bound 25(OH)D is uniformly inaccessible.

The liver-disease experiment shows why carrier concentration matters

A companion 1986 study examined people with liver disease, a useful natural setting because both DBP and albumin can fall. Compared with controls, affected participants had lower total 25(OH)D and a higher percentage of free 25(OH)D, while absolute free 25(OH)D was broadly equivalent. Total 25(OH)D correlated positively with DBP and albumin, whereas the percentage free moved in the opposite direction.

That finding is not a general rule that low total 25(OH)D in liver disease is harmless. It demonstrates something more precise: when the proteins determining binding capacity change substantially, the mapping between total and free concentration can change. This is why the physiological context supplied by carrier proteins matters when a laboratory result is interpreted.

Here, the liver-disease evidence is relevant specifically because it shows how altered carrier concentrations can change circulating binding and partitioning. The result is being used as an altered-binding experiment, not as a claim that every low total result in liver disease has the same meaning.

Common DBP phenotypes change the scale more subtly

Rare complete loss of DBP is biologically dramatic, but most people have DBP rather than no DBP. Common GC variants produce DBP phenotypes associated with more modest differences in circulating DBP and vitamin D measures. Sollid and colleagues examined 472 adults from a randomised vitamin D supplementation study and compared total 25(OH)D, directly measured free 25(OH)D and DBP phenotype.

Phenotype-related differences were more evident for total 25(OH)D and DBP than for directly measured free 25(OH)D. Importantly, supplementation increased vitamin D measures without evidence that the response fundamentally split into different physiological systems according to DBP phenotype, sex or age. This supports a graded model: ordinary carrier variation can influence the relationship between total and free, but it does not resemble complete carrier absence.

This distinction also prevents a common error in discussions of Vitamin D Genetics. A common polymorphism and a homozygous loss-of-function state are not interchangeable evidence.

Complete human DBP loss is an unusually strong causal test

The most striking human evidence comes from people in whom the GC gene cannot produce functional circulating DBP. Henderson and colleagues reported a woman with a homozygous GC deletion and essentially absent DBP. Her total 25(OH)D concentration was extraordinarily low, about 0.079 ng/mL, yet directly measured free 25(OH)D was 1.8 pg/mL. Her carrier and unaffected siblings had free values of 3.4 and 3.2 pg/mL respectively. Calcium and parathyroid hormone regulation were comparatively preserved despite a total concentration that, in an ordinary patient, would look profoundly deficient.

This is powerful causal evidence that DBP is a major determinant of the measured total circulating pool. It is not evidence that vitamin D physiology is normal without DBP. The proband had important musculoskeletal disease, including osteopenia and fractures, and subsequent correspondence questioned aspects of the phenotype. A single rare genetic case cannot tell us what routine low total 25(OH)D means in people with normal carrier biology.

An unrelated 2021 case strengthened the carrier argument. Banerjee and colleagues described a patient with a homozygous pathogenic GC splice-site variant, undetectable DBP by mass spectrometry and extremely low total vitamin D metabolites, but without the major metabolic bone disease that might be predicted from the total values alone. Two independent rare cases make the carrier-dependence conclusion harder to dismiss, while remaining far too unusual to define ordinary clinical thresholds.

Free does not mean universally active, and bound does not mean inert

The free-hormone idea is useful as a starting model, not a complete account of vitamin D biology. Unbound molecules participate in exchange with bound pools, but the studies examined here do not map every route by which tissues obtain vitamin D metabolites. A circulating binding experiment therefore cannot establish that DBP-bound 25(OH)D is biologically unavailable everywhere. The secure conclusion is narrower: DBP creates a large circulating bound reservoir and strongly influences total concentration.

This is why circulating fractions should not be confused with tissue response. Vitamin D Status vs Vitamin D Effect addresses the broader distinction between what is present in blood and what biology ultimately does with it. A blood compartment can constrain availability without directly measuring intracellular activation, receptor engagement or downstream response.

The same caution applies to albumin-bound 25(OH)D. Its weaker binding supports more rapid exchange with free 25(OH)D, but the evidence examined here does not establish a universal tissue-by-tissue rule that free plus albumin-bound concentration is the single biologically decisive quantity.

What the evidence supports

Taken together, the studies support a coherent physiological model. Total 25(OH)D is the sum of a dominant DBP-bound pool, a smaller albumin-bound pool and a very small free pool. DBP concentration and affinity help determine how much 25(OH)D can be carried in the total compartment. Albumin contributes lower-affinity binding. The fractions exchange, so they are related rather than independent measurements.

The rare GC loss-of-function cases provide the strongest causal demonstration that an extremely low total value can, under an extreme carrier abnormality, coexist with a less extreme free concentration and less disruption of mineral homeostasis than the total number alone would suggest. The common-phenotype and liver-disease studies show the same principle at less extreme scales: binding context can modify the relationship between total and free.

None of this abolishes the value of total 25(OH)D. In ordinary physiology, total and free commonly move together. The evidence instead explains why that relationship is conditional on carrier biology and why exceptional states deserve more careful interpretation.

How the key studies generated the evidence

The 1986 binding study used ultrafiltration and experimental manipulation of serum binding proteins to estimate free fraction and binding affinity. Its strength is direct biochemical interrogation of human serum. Its limitations include its age, modest sample size and the analytical constraints of the period. It established the architecture of binding more securely than it established modern clinical decision rules.

Sollid’s study added a different evidential design. It used a randomised supplementation cohort, LC-MS/MS for total 25(OH)D, direct measurement of free 25(OH)D and DBP phenotyping. That combination allowed ordinary genetic variation and treatment response to be examined together. It does not, however, establish that one laboratory measure produces better patient outcomes than another.

The GC-null reports are genetic natural experiments rather than population studies. Their mechanistic leverage is unusually high because the carrier itself is removed by genotype. Their generalisability is correspondingly low. The correct use of these cases is to establish what DBP can causally do to circulating concentrations, not to rewrite ordinary vitamin D assessment around two exceptional patients.

Why percentages can mislead

A percentage free value and an absolute free concentration answer different questions. If total 25(OH)D falls because carrier capacity falls, the percentage of the remaining 25(OH)D that is free can rise even when the absolute free concentration is unchanged. The liver-disease study illustrates this clearly. Saying only that the “free fraction is higher” can therefore sound more biologically dramatic than the absolute measurement warrants.

The reverse problem also occurs when a reader sees a tiny percentage and assumes it must be unimportant. A small unbound pool can be continuously replenished from bound reservoirs. Concentration at one moment does not describe turnover, exchange, uptake or intracellular metabolism. The fractions need to be understood dynamically rather than as sealed containers.

Limits of the physiological model

The evidence is strongest for circulating binding and for the proposition that carrier biology influences measured total concentration. It is weaker for universal claims about which fraction best predicts tissue action. The studies examined here do not measure every tissue, do not define a universal free 25(OH)D target, and do not show that albumin-bound 25(OH)D has identical accessibility across organs.

Measurement itself adds another boundary. Direct free assays and calculated estimates are not interchangeable, a problem developed in Variability in Vitamin D Measurements and in the paired measurement Full Study. The correct physiological conclusion is therefore neither “total is all that matters” nor “free is all that matters.” It is that the compartments are physically distinct, tightly related and conditionally informative.

Primary studies

Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Journal of Clinical Endocrinology & Metabolism, 1986. Assessment of the Free Fraction of 25-Hydroxyvitamin D in Serum and Its Regulation by Albumin and the Vitamin D-Binding Protein.

Bikle DD, Halloran BP, Gee E, Ryzen E, Haddad JG. Journal of Clinical Investigation, 1986. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels.

Sollid ST et al. European Journal of Endocrinology, 2016. Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D.

Henderson CM et al. New England Journal of Medicine, 2019. Vitamin D-Binding Protein Deficiency and Homozygous Deletion of the GC Gene.

Banerjee RR et al. Journal of the Endocrine Society, 2021. Very Low Vitamin D in a Patient With a Novel Pathogenic Variant in the GC Gene That Encodes Vitamin D-Binding Protein.

Related reading

Original sources